This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Endotarget Inc.. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Innovations of Hongjoong Kim in Targeted Degradation of Bruton's Tyrosine Kinase
Introduction
Hongjoong Kim is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmacology, particularly in the development of compounds aimed at targeted degradation of proteins involved in various diseases.
Latest Patents
Hongjoong Kim holds a patent for "Substituted pyrimidines for the targeted degradation of Bruton's tyrosine kinase." This patent describes compounds that serve as degraders and/or inhibitors of Bruton's tyrosine kinase (BTK). The compounds are designed to bind to both BTK and E3 ubiquitin ligase (CRBN), facilitating the degradation of BTK through the proteasome. The patent outlines methods for synthesizing these compounds and discusses their potential pharmacological activities in treating proliferative diseases and autoimmune disorders, including hematological cancers and rheumatoid arthritis.
Career Highlights
Hongjoong Kim is associated with Endotarget Inc., where he continues to innovate in the field of targeted therapies. His work focuses on developing novel compounds that can effectively address complex medical conditions.
Collaborations
He has collaborated with notable colleagues, including Xianyou Peng and Borui Kang, to advance research and development in his field.
Conclusion
Hongjoong Kim's innovative work in the targeted degradation of Bruton's tyrosine kinase represents a significant advancement in therapeutic strategies for treating serious health conditions. His contributions continue to impact the field of pharmacology positively.